MedPath

Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension

Not Applicable
Conditions
Pulmonary Arterial Hypertension
Registration Number
NCT01905189
Lead Sponsor
University Hospital, Caen
Brief Summary

Pulmonary arterial hypertension is a disease characterised by pathological changes in the pulmonary arteries leading to a progressive increase in pulmonary vascular resistance and pulmonary artery pressure. Right ventricular failure is the main cause of death in patients with pulmonary arterial hypertension, and the ability of the right ventricle to adapt to the progressive increase in pulmonary vascular resistance associated with changes to the pulmonary vasculature in pulmonary arterial hypertension is the main determinant of a patient's functional capacity and survival.

Right ventricular dyssynchrony was present in a substantial proportion of patients with pulmonary arterial hypertension and this dyssynchrony adversely affected right ventricular function.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
15
Inclusion Criteria
  • Pulmonary hypertension type I, III, IV, V Dana Point classification
  • NYHA classification equal or superior to stage II
  • During right catetherization : cardiac index inferior or equal 2.5 L/mn/m2 and atrial pressure superior or equal 10 mmHg OR cardiac index equal or inferior to 2.2 L/mn/m2
  • Optimal therapy considered by the referring specialist practioner of the patient
Exclusion Criteria
  • Minor or incapacitated adult
  • Pregnancy
  • Unability to give free and informed consent
  • Pulmonary hypertension type II Dana Point classification
  • Eisenmenger syndrome
  • Patent foramen ovale
  • Left bundle-brach block
  • Pulmonary hypertension exacerbation
  • Medical clinical situation considered inappropriate by the investigator
  • Patient eligible for a heart-lung transplant
  • Patient eligible for pulmonary endarterectomy
  • Patient with poor echogenicity
  • Filter in the inferior vena cava

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
cardiac index measured during right catheterizationAfter two minutes of right stimulation
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Caen UH

🇫🇷

Caen, Basse-Normandie, France

Caen UH
🇫🇷Caen, Basse-Normandie, France
Paul-Ursmar Milliez
Principal Investigator
Arnaud Pellissier
Sub Investigator
Sophie Gomes
Sub Investigator
Emmanuel Bergot
Sub Investigator
Farzin Beygui
Sub Investigator
Fabien Labombarda
Sub Investigator
Alain Lebon
Sub Investigator
Vincent Roule
Sub Investigator
Rémi Sabatier
Sub Investigator
Eric Saloux
Sub Investigator
Patrice Scanu
Sub Investigator
Laure Champ-Rigot
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.